Skin Sensitization Testing—What’s Next?
AbstractThere is an increasing demand for alternative in vitro methods to replace animal testing, and, to succeed, new methods are required to be at least as accurate as existing in vivo tests. However, skin sensitization is a complex process requiring coordinated and tightly regulated interactions between a variety of cells and molecules. Consequently, there is considerable difficulty in reproducing this level of biological complexity in vitro, and as a result the development of non-animal methods has posed a major challenge. However, with the use of a relevant biological system, the high information content of whole genome expression, and comprehensive bioinformatics, assays for most complex biological processes can be achieved. We propose that the Genomic Allergen Rapid Detection (GARD™) assay, developed to create a holistic data-driven in vitro model with high informational content, could be such an example. Based on the genomic expression of a mature human dendritic cell line and state-of-the-art machine learning techniques, GARD™ can today accurately predict skin sensitizers and correctly categorize skin sensitizing potency. Consequently, by utilizing advanced processing tools in combination with high information genomic or proteomic data, we can take the next step toward alternative methods with the same predictive accuracy as today’s in vivo methods—and beyond. View Full-Text
Share & Cite This Article
Grundström, G.; Borrebaeck, C.A. Skin Sensitization Testing—What’s Next? Int. J. Mol. Sci. 2019, 20, 666.
Grundström G, Borrebaeck CA. Skin Sensitization Testing—What’s Next? International Journal of Molecular Sciences. 2019; 20(3):666.Chicago/Turabian Style
Grundström, Gunilla; Borrebaeck, Carl A. 2019. "Skin Sensitization Testing—What’s Next?" Int. J. Mol. Sci. 20, no. 3: 666.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.